SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Basser, R. L. Articles by Begley, C. G. Search for Related Content PubMed PubMed Citation Articles by Basser, R. L. Articles by Begley, C. G. Related Collections Hematopoiesis and Stem Cells Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 April 2002, Vol. 99, No. 7, pp. 2599-2602 BRIEF REPORT Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor Russell L. Basser, Elizabeth O'Flaherty, Michael Green, Maria Edmonds, Janet Nichol, Dora M. Menchaca, Brian Cohen, and C. Glenn Begley From the Centre for Developmental Cancer Therapeutics, Ludwig Institute for Cancer Research, Department of Haematology and Medical Oncology, Rotary Bone Marrow Research Laboratories, Royal Melbourne Hospital; Walter and Eliza Hall Institute for Medical Research; Department of Haematology and Medical Oncology, Western Hospital, Parkville, Victoria, Australia; Amgen Australia, Kew; and Amgen, Thousand Oaks, CA. Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor. Samples of the patient's bone marrow showed trilineage hypoplasia with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor. To our knowledge, this is the first report of an aplastic anemia-like syndrome associated with neutralizing antibodies to TPO. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Kalota and A. M. Gewirtz A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells Blood, January 7, 2010; 115(1): 89 - 93. [Abstract] [Full Text] [PDF] S. Perreault and J. Burzynski Romiplostim: A novel thrombopoiesis-stimulating agent Am. J. Health Syst. Pharm., May 1, 2009; 66(9): 817 - 824. [Abstract] [Full Text] [PDF] M. N. Samtani, J. J. Perez-Ruixo, K. H. Brown, D. Cerneus, and C. J. Molloy Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG-TPOm) After Single Intravenous Dose Administration in Healthy Subjects J. Clin. Pharmacol., March 1, 2009; 49(3): 336 - 350. [Abstract] [Full Text] [PDF] T. Gernsheimer Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis Oncologist, January 1, 2009; 14(1): 12 - 21. [Abstract] [Full Text] [PDF] W. Nogami, H. Yoshida, K. Koizumi, H. Yamada, K. Abe, A. Arimura, N. Yamane, K. Takahashi, A. Yamane, A. Oda, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis Haematologica, October 1, 2008; 93(10): 1495 - 1504. [Abstract] [Full Text] [PDF] A. Yamane, T. Nakamura, H. Suzuki, M. Ito, Y. Ohnishi, Y. Ikeda, and Y. Miyakawa Interferon-{alpha}2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes Blood, August 1, 2008; 112(3): 542 - 550. [Abstract] [Full Text] [PDF] T. B. Gernsheimer The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura Hematology, January 1, 2008; 2008(1): 219 - 226. [Abstract] [Full Text] [PDF] C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann. Onc., November 1, 2007; 18(11): 1842 - 1850. [Abstract] [Full Text] [PDF] D. J. Kuter New thrombopoietic growth factors Blood, June 1, 2007; 109(11): 4607 - 4616. [Abstract] [Full Text] [PDF] B. Andemariam, B. Psaila, and J. B. Bussel Novel Thrombopoietic Agents Hematology, January 1, 2007; 2007(1): 106 - 113. [Abstract] [Full Text] [PDF] J. B. Bussel, D. J. Kuter, J. N. George, R. McMillan, L. M. Aledort, G. T. Conklin, A. E. Lichtin, R. M. Lyons, J. Nieva, J. S. Wasser, et al. AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP N. Engl. J. Med., October 19, 2006; 355(16): 1672 - 1681. [Abstract] [Full Text] [PDF] M. Pick, C. Perry, T. Lapidot, C. Guimaraes-Sternberg, E. Naparstek, V. Deutsch, and H. Soreq Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis Blood, April 15, 2006; 107(8): 3397 - 3406. [Abstract] [Full Text] [PDF] T. Orita, H. Tsunoda, N. Yabuta, K. Nakano, T. Yoshino, Y. Hirata, T. Ohtomo, J.-i. Nezu, H. Sakumoto, K. Ono, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor Blood, January 15, 2005; 105(2): 562 - 566. [Abstract] [Full Text] [PDF] R. Thorpe and S. J Swanson Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins Clin. Vaccine Immunol., January 1, 2005; 12(1): 28 - 39. [Full Text] [PDF] K. Inagaki, T. Oda, Y. Naka, H. Shinkai, N. Komatsu, and H. Iwamura Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities Blood, July 1, 2004; 104(1): 58 - 64. [Abstract] [Full Text] [PDF] M. Stickler, N. Rochanayon, O. J. Razo, J. Mucha, W. Gebel, N. Faravashi, R. Chin, S. Holmes, and F. A. Harding An In Vitro Human Cell-Based Assay to Rank the Relative Immunogenicity of Proteins Toxicol. Sci., February 1, 2004; 77(2): 280 - 289. [Abstract] [Full Text] [PDF] M. Drouet, F. Mourcin, N. Grenier, V. Leroux, J. Denis, J.-F. Mayol, P. Thullier, J.-J. Lataillade, and F. Herodin Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis Blood, February 1, 2004; 103(3): 878 - 885. [Abstract] [Full Text] [PDF] G. Giovannoni Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies Neurology, November 11, 2003; 61(90095): S13 - 17. [Abstract] [Full Text] L. A. Ladewski, S. M. Belknap, J. R. Nebeker, O. Sartor, E. A. Lyons, T. C. Kuzel, M. S. Tallman, D. W. Raisch, A. R. Auerbach, G. T. Schumock, et al. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project J. Clin. Oncol., October 15, 2003; 21(20): 3859 - 3866. [Abstract] [Full Text] [PDF] D. J. Kuter and C. G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood, November 15, 2002; 100(10): 3457 - 3469. [Abstract] [Full Text] [PDF] I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 193 - 212. [Abstract] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020